Zobrazeno 1 - 10
of 250
pro vyhledávání: '"Gerwin Huls"'
Autor:
Federico Mosna, Erika Borlenghi, Mark Litzow, John C. Byrd, Cristina Papayannidis, Cristina Tecchio, Felicetto Ferrara, Guido Marcucci, Roberto Cairoli, Elizabeth A. Morgan, Carmela Gurrieri, Cecilia C.S. Yeung, H. Joachim Deeg, Debora Capelli, Anna Candoni, Jason R. Gotlib, Monia Lunghi, Sheeja Pullarkat, Francesco Lanza, Sara Galimberti, Fabio Forghieri, Adriano Venditti, Moreno Festuccia, Ernesta Audisio, Denise Marvalle, Gian Matteo Rigolin, Giovanni Roti, Eros DiBona, Giuseppe Visani, Francesco Albano, Ann-Kathrin Eisfeld, Peter Valent, Gerwin Huls, Gautam Borthakur, Mauro Krampera, Giovanni Martinelli, Nicolaus Kröger, Alessandra Sperotto, Michele Gottardi
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Acute Myeloid Leukemia is mainly a disease of the elderly: however, the knowledge on the outcomes of treatment in core binding factor AML (CBFAML) in older population, is limited. We retrospectively collected data on 229 patients with CBF- AML follow
Externí odkaz:
https://doaj.org/article/f2c7a10b80a14607b116ee33cafabed3
Autor:
Maria L. Salustiano-Bandeira, Amanda Moreira-Aguiar, Diego A. Pereira-Martins, Juan L. Coelho-Silva, Isabel Weinhäuser, Pedro L. França-Neto, Aleide S. Lima, Ana S. Lima, Anemari R. Baccarin, Fernanda B. Silva, Manuela A. de Melo, Fernanda S. Niemann, Luciana Nardinelli, César A. Ortiz Rojas, Bruno K. Duarte, Aderson S. Araujo, Elisa A. Azevedo, Clarice N. Morais, Lorena L. Figueiredo-Pontes, Jan J. Schuringa, Gerwin Huls, Israel Bendit, Eduardo M. Rego, Sara T. Olalla Saad, Fabiola Traina, Marcos A. Bezerra, Antonio R. Lucena-Araujo
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/67ef150b7ee54451934361d769848375
Autor:
Niek G. van der Maas, Jurjen Versluis, Kazem Nasserinejad, Joost van Rosmalen, Thomas Pabst, Johan Maertens, Dimitri Breems, Markus Manz, Jacqueline Cloos, Gert J. Ossenkoppele, Yngvar Floisand, Patrycja Gradowska, Bob Löwenberg, Gerwin Huls, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract Randomized controlled trials (RCTs) are the gold standard to establish the benefit-risk ratio of novel drugs. However, the evaluation of mature results often takes many years. We hypothesized that the addition of Bayesian inference methods a
Externí odkaz:
https://doaj.org/article/623b04e635e3492980510900ad96507c
Autor:
Yusheng Lin, Ghizlane Choukrani, Lena Dubbel, Lena Rockstein, Jimena Alvarez Freile, Yuzhu Qi, Valerie Wiersma, Hao Zhang, Karl-Wilhelm Koch, Emanuele Ammatuna, Jan Jacob Schuringa, Tom van Meerten, Gerwin Huls, Edwin Bremer
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-18 (2024)
Abstract Background VISTA is a well-known immune checkpoint in T cell biology, but its role in innate immunity is less established. Here, we investigated the role of VISTA on anticancer macrophage immunity, with a focus on phagocytosis, macrophage po
Externí odkaz:
https://doaj.org/article/60adcfc1ae254d998496249d73aaad31
Autor:
Hester F Lingsma, David van Klaveren, Arjan A van de Loosdrecht, Anna van Rhenen, Otto Visser, Valery E P P Lemmens, Nikki van Leeuwen, Gerwin Huls, Z L Rana Kaplan, Eduardus F M Posthuma, Danielle van Lammeren-Venema, Tjeerd J F Snijders, Catharina H M J van Elssen, Peter A von dem Borne, Nicole M A Blijlevens, Jan J Cornelissen, Marc H G P Raaijmakers, Avinash G Dinmohamed
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Objective Acute myeloid leukaemia (AML) prognosis is enhanced with intensive remission induction chemotherapy (ICT) in eligible patients. However, ICT eligibility perceptions may differ among healthcare professionals. This nationwide, population-base
Externí odkaz:
https://doaj.org/article/1ccfa978daa64b508cdfbda59b2174a6
Autor:
Hanneke J C M Wouters, Bruce H R Wolffenbuttel, Anneke C Muller Kobold, Thera P Links, Gerwin Huls, Melanie M van der Klauw
Publikováno v:
Endocrine Connections, Vol 12, Iss 12, Pp 1-11 (2023)
Hypothyroidism is associated with a decreased health-related quality of life (HRQoL). We hypothesized that individuals with hypothyroidism (defined as us e of thyroid hormone (TH)) and especially those having an impaired HRQoL are characterized by a
Externí odkaz:
https://doaj.org/article/ab669391c7434504a01e0808b0d2d79d
Autor:
Ghizlane Choukrani, Nienke Visser, Natasha Ustyanovska Avtenyuk, Mirjam Olthuis, Glenn Marsman, Emanuele Ammatuna, Harm Jan Lourens, Toshiro Niki, Gerwin Huls, Edwin Bremer, Valerie R. Wiersma
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract Acute myeloid leukemia (AML) is a malignancy still associated with poor survival rates, among others, due to frequent occurrence of therapy-resistant relapse after standard-of-care treatment with cytarabine (AraC). AraC triggers apoptotic ce
Externí odkaz:
https://doaj.org/article/744707850025474188f77817ec125057
Autor:
Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Gerwin Huls
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and
Externí odkaz:
https://doaj.org/article/71614de5d82b474e855269ada1ea2dee
Autor:
Nienke Visser, Levi Collin Nelemans, Yuan He, Harm Jan Lourens, Macarena González Corrales, Gerwin Huls, Valerie R. Wiersma, Jan Jacob Schuringa, Edwin Bremer
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
In recent years, the therapeutic (re)activation of innate anticancer immunity has gained prominence, with therapeutic blocking of the interaction of Signal Regulatory Protein (SIRP)-α with its ligand CD47 yielding complete responses in refractory an
Externí odkaz:
https://doaj.org/article/433d8659aff946d7b49c0e7573e80c22
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 10, Pp n/a-n/a (2023)
Externí odkaz:
https://doaj.org/article/3653626ead6f476187270d72379e0044